Linus Jönsson

About me
Publications
Grants
CV
Public outreach and news

About me

Linus Jönsson was born in Lund in 1975. He graduated with a medical degree from Uppsala University in 2000 and a Master’s in business and economics from the Stockholm School of Economics in 2001.

Linus Jönsson earned his PhD from Karolinska Institutet in 2003, became a registered doctor in 2004 and docent in 2019. He has previously worked with commissioned health economics research and in the drugs industry.

Linus Jönsson was appointed Professor of Health Economics at Karolinska Institutet on 24 January 2023.

Articles

Article: PHARMACOECONOMICS (AUCKLAND). 2024;:1-17
Costs of Care in Relation to Alzheimer's Disease Severity in Sweden: A National Registry-Based Cohort Study
Aye S; Frisell O; Zetterberg H; Skillback TB; Kern S; Eriksdotter M; Aho E; Xia X; Winblad B; Wimo A; Joensson L
Article: BRAIN COMMUNICATIONS. 2024;6(6):fcae371
A glycan biomarker predicts cognitive decline in amyloid- and tau-negative patients
Zhou RZ; Duell F; Axenhus M; Joensson L; Winblad B; Tjernberg LO; Schedin-Weiss S
Article: VALUE IN HEALTH. 2024;26(12):S419
IPECAD MODELING WORKSHOP 2023 CROSS COMPARISON CHALLENGE ON COST-EFFECTIVENESS MODELS IN ALZHEIMER'S DISEASE AND RELATED DEMENTIAS
Handels R; Herring W; Kamgar F; Gustavsson A; Skoldunger A; Wimo A; Tate A; Winblad B; Stellick CB; Bruck C; Green C; de Kok I; Hlavka J; Mar J; Urbich M; Soto-Gordoa M; Pemberton-Ross P; Aye S; Jonsson L
Article: THE LANCET REGIONAL HEALTH. EUROPE. 2024;45:101029
Prevalence of dementia diagnosis in Sweden by geographical region and sociodemographic subgroups: a nationwide observational study
Ding M; Ek S; Aho E; Jonsson L; Schmidt-Mende K; Modig K
Article: VALUE IN HEALTH. 2024;:S1098-3015(24)02790-6
New International Pharmaco-Economic Collaboration on Alzheimer's Disease (IPECAD) Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use Cases.
Handels R; Herring WL; Grimm S; Sköldunger A; Winblad B; Wimo A; Jönsson L
Article: THE JOURNALS OF GERONTOLOGY. SERIES A, BIOLOGICAL SCIENCES AND MEDICAL SCIENCES. 2024;79(4):glae010
Associations of Orthostatic Hypotension and Frailty With Dementia and Mortality in Older Adults: A Population-Based Cohort Study
Xia X; Jonsson L; Tazzeo C; Qiu C; Rizzuto D; Laukka EJ; Grande G; Fratiglioni L; Vetrano DL
Article: THE JOURNAL OF HEADACHE AND PAIN. 2024;25(1):45
Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumab
Jonsson L; Awad SF; Regnier SA; Talon B; Kymes S; Lee XY; Goadsby PJ
Article: ALZHEIMER'S RESEARCH AND THERAPY. 2024;16(1):48
Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease
Jonsson L; Ivkovic M; Atri A; Handels R; Gustavsson A; Hahn-Pedersen JH; Leon T; Lilja M; Gundgaard J; Raket LL
Article: ALZHEIMER'S AND DEMENTIA. 2024;20(2):809-818
Predicting sojourn times across dementia disease stages, institutionalization, and mortality
Tate AE; Bouteloup V; van Maurik IS; Jean D; Mank A; Speh A; Boilet V; van Harten A; Eriksdotter M; Wimo A; Dufouil C; van der Flier WM; Joensson L
Article: THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE. 2024;11(4):928-942
Optimising Alzheimer's Disease Diagnosis and Treatment: Assessing Cost-Utility of Integrating Blood Biomarkers in Clinical Practice for Disease-Modifying Treatment
Aye S; Handels R; Winblad B; Jonsson L
Article: THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE. 2024;11(1):155-161
Estimates of Current Capacity for Diagnosing Alzheimer's Disease in Sweden and the Need to Expand Specialist Numbers
Mattke S; Gustavsson A; Jacobs L; Kern S; Palmqvist S; Eriksdotter M; Skoog I; Winblad B; Wimo A; Jonsson L
Article: THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE. 2024;11(2):329-338
Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project
Malzbender K; Barbarino P; Ferrell PB; Bradshaw A; Brookes AJ; Diaz C; van der Flier WM; Georges J; Hansson O; Hartmanis M; Jonsson L; Krishnan R; MacLeod T; Mangialasche F; Mecocci P; Minguillon C; Middleton L; Pla S; Sardi SP; Scholl M; Suarez-Calvet M; Weidner W; Visser PJ; Zetterberg H; Bose N; Solomon A; Kivipelto M
Journal article: VALUE IN HEALTH. 2023;26(12):s411
MSR98 Generate Synthetic Data in R for a Hypothetical Alzheimer's Disease Trial
Handels R; Jönsson L; Raket LL
Journal article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2023;39(S1):s42
OP142 Progression Analysis Versus Traditional Methods To Quantify Slowing Of Disease Progression In Alzheimer’s Disease
Jönsson L; Ivkovic M; Handels R; Gustavsson A; León T; Hahn-Pedersen JH; Raket LL
Journal article: VALUE IN HEALTH. 2023;26(12):s419
MSR136 IPECAD Modeling Workshop 2023 Cross Comparison Challenge on Cost-Effectiveness Models in Alzheimer's Disease and Related Dementias
Handels R; Herring W; Kamgar F; Gustavsson A; Skoldunger A; Wimo A; Tate A; Winblad B; Stellick CB; Bruck C; Green C; de Kok I; Hlavka J; Mar J; Urbich M; Soto-Gordoa M; Pemberton-Ross P; Aye S; Jönsson L; Participants W
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S22)
Associations of orthostatic hypotension and frailty with dementia and mortality in older adults: a cohort study
Xia X; Tazzeo C; Jönsson L; Qiu C; Rizzuto D; Laukka EJ; Okoye C; Grande G; Fratiglioni L; Vetrano DL
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S21)
Estimating Treatment Effects of Disease‐modifying Drugs: Traditional Methods vs. Accelerated Failure Time Models and Progression Analysis
Atri A; Ivkovic M; Jönsson L; Gustavsson A; Léon T; Hahn‐Pedersen JH; Handels R; Raket LL
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S23)
The potential cost‐effectiveness of roflumilast drug treatment in mild cognitive impairment
Handels R; Grimm S; Blokland A; Possemis N; Ramakers IHGB; Sambeth A; Verhey FRJ; Vos SJB; Joore M; Prickaerts J; Jönsson L
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S21)
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD
Jönsson L; Gustavsson A; Handels R
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S21)
Cost‐effectiveness of amyloid‐targeting therapies: modelling based on 5724 biomarker positive AD patients in the Swedish Registry of Cognitive Disorders
Jönsson L; Skillback T; Kern S; Winblad B; Blennow K; Eriksdotter M; Zetterberg H; Wimo A
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S22)
Predicting Sojourn Times across Dementia Disease Stages, Institutionalization, and Mortality
Tate A; Bouteloup V; van Maurik IS; Mank A; Speh A; Eriksdotter M; Wimo A; Dufouil C; van der Flier WM; Jönsson L
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S19)
Health‐related quality of life in full spectrum of Alzheimer’s disease: a longitudinal analysis
Aye S; Bouteloup V; Jean D; Jönsson L
Article: ALZHEIMER'S RESEARCH AND THERAPY. 2023;15(1):200
Health-related quality of life in subjective cognitive decline and mild cognitive impairment: a longitudinal cohort analysis
Aye S; Bouteloup V; Tate A; Wimo A; Handels R; Jean D; Winblad B; Joensson L
Article: EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH. 2023;23(7):797-803
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trial
Jonsson L; Regnier SA; Kymes S; Awad SF; Talon B; Lee XY; Goadsby PJ
Article: ALZHEIMER'S AND DEMENTIA. 2023;19(8):3458-3471
The value of maintaining cognition in patients with mild cognitive impairment: The innovation headroom and potential cost-effectiveness of roflumilast
Handels R; Grimm S; Blokland A; Possemis N; Ramakers I; Sambeth A; Verhey F; Vos S; Joore M; Prickaerts J; Jonsson L
Article: CLINICAL DRUG INVESTIGATION. 2023;43(7):529-540
Estimating the Product Lifecycle Value of Trastuzumab Based on Registry Data in Sweden
Justo N; Wilking N; Jonsson L
Article: ALZHEIMER'S AND DEMENTIA. 2023;19(7):3244-3249
A glycan epitope correlates with tau in serum and predicts progression to Alzheimer's disease in combination with APOE4 allele status
Zhou RZ; Vetrano DL; Grande G; Duell F; Jonsson L; Laukka EJ; Fredolini C; Winblad B; Tjernberg L; Schedin-Weiss S
Article: ALZHEIMER'S AND DEMENTIA. 2023;19(7):2865-2873
The worldwide costs of dementia in 2019
Wimo A; Seeher K; Cataldi R; Cyhlarova E; Dielemann JL; Frisell O; Guerchet M; Jonsson L; Malaha AK; Nichols E; Pedroza P; Prince M; Knapp M; Dua T
Article: THE LANCET REGIONAL HEALTH. EUROPE. 2023;29:100657
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint
Joensson L; Wimo A; Handels R; Johansson G; Boada M; Engelborghs S; Froelich L; Jessen F; Kehoe PG; Kramberger M; de Mendon A; Ousset PJ; Scarmeas N; Visser PJ; Waldemar G; Winblad B
Journal article: ALZHEIMER'S AND DEMENTIA. 2023;19(S8)
Health‐economic innovation headroom in mild cognitive impairment due to Alzheimer’s diseas
Handels R; Jönsson L
Article: ALZHEIMER'S AND DEMENTIA. 2023;19(5):1800-1820
Cost-effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross-comparison challenge
Handels RLH; Green C; Gustavsson A; Herring WL; Winblad B; Wimo A; Skoldunger A; Karlsson A; Anderson R; Belger M; Bruck C; Espinosa R; Hlavka JP; Jutkowitz E; Lin P-J; Mendez ML; Mar J; Shewmaker P; Spackman E; Tafazzoli A; Tysinger B; Jonsson L
Article: ALZHEIMER'S AND DEMENTIA. 2023;19(3):999-1008
Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program
Wimo A; Handels R; Antikainen R; Eriksdotter M; Jonsson L; Knapp M; Kulmala J; Laatikainen T; Lehtisalo J; Peltonen M; Skoldunger A; Soininen H; Solomon A; Strandberg T; Tuomilehto J; Ngandu T; Kivipelto M
Journal article: US NEUROLOGY. 2023;19(1):14
Lecanemab: The Price of a Breakthrough
Wimo A; Jönsson L; Johansson G; Winblad B
Article: ALZHEIMER'S AND DEMENTIA: DIAGNOSIS, ASSESSMENT AND DISEASE MONITORING. 2023;15(1):e12422
Effect of mortality in cost-effectiveness modeling of disease-modifying treatment for Alzheimer's disease
Aye S; Jonsson L; Gustavsson A; Tate A; Ptacek SG; Eriksdotter M
Article: FRONTIERS IN NEUROLOGY. 2023;14:1175922
Precision medicine in neurodegeneration: the IHI-PROMINENT project
Tate A; Suarez-Calvet M; Ekelund M; Eriksson S; Eriksdotter MM; Van der Flier W; Georges J; Kivipelto MG; Kramberger M; Lindgren P; Lopez JDG; Lotjonen J; Persson S; Pla S; Solomon A; Thurfjell L; Wimo A; Winblad B; Jonsson L
Journal article: VALUE IN HEALTH. 2022;25(12):s31-s32
CO72 Predicting Sojourn Times by Dementia Stages: Evidence From 76,747 Patients in the Swedish National Registry for Cognitive Disorders (SVEDEM)
Tate A; Jönsson L
Journal article: VALUE IN HEALTH. 2022;25(12):s483
SA3 Effect of Mortality on Cost-Effectiveness Modeling of Disease-Modifying Treatment for Alzheimer's Disease
Aye S; Jönsson L
Journal article: VALUE IN HEALTH. 2022;25(12):s436
PCR237 Effect of Eptinezumab on Utility Scores in Patients With Migraine: Results From the Deliver Study
Jönsson L; Regnier; Kymes S; Talon B; Awad S; Lee X; Goadsby P
Journal article: VALUE IN HEALTH. 2022;25(12):s390
PCR4 Disease-Specific Quality-of-Life Measures Mapped to the EQ-5D in a Chronic Disorder With Recurrent Attacks: Analysis of the Deliver Trial in Patients With Migraine
Jönsson L; Regnier; Kymes S; Awad S; Talon B; Lee X; Goadsby P
Journal article: ALZHEIMER'S AND DEMENTIA. 2022;18(S11)
Costs of dementia in Europe: a systematic literature review and meta‐analysis
Jönsson L; Frisell O; Wimo A
Journal article: ALZHEIMER'S AND DEMENTIA. 2022;18(S8)
A longitudinal study on quality of life along the spectrum of Alzheimer’s disease
Mank A; Rijnhart JJM; van Maurik IS; Jönsson L; Handels R; Bakker ED; Teunissen CE; van Berckel BN; van Harten AC; Berkhof J; van der Flier WM
Article: ALZHEIMER'S RESEARCH AND THERAPY. 2022;14(1):132
A longitudinal study on quality of life along the spectrum of Alzheimer's disease
Mank A; Rijnhart JJM; van Maurik IS; Jonsson L; Handels R; Bakker ED; Teunissen CE; van Berckel BNM; van Harten AC; Berkhof J; van der Flier WM
Article: MOVEMENT DISORDERS. 2022;37(7):1425-1431
Sensitivity to Change and Patient-Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data-Driven Analysis
Krismer F; Seppi K; Jonsson L; Astrom DO; Berger A-K; Simonsen J; Gordon MF; Wenning GK; Poewe W
Article: THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE. 2022;9(1):12-21
Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention
Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jonsson L; Middleton L
Article: ALZHEIMER’S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS. 2022;8(1):e12360
Health economic modeling for Alzheimer's disease: Expert perspectives
Landeiro F; Morton J; Gustavsson A; Potashman M; Lecomte P; Belger M; Thompson R; Roncancio-Diaz E; Jhuti G; Butler C; Jonsson L; Handels R; Gray AM
Article: BMC PSYCHIATRY. 2021;21(1):634
Predicting time to relapse in patients with schizophrenia according to patients' relapse history: a historical cohort study using real-world data in Sweden
Jorgensen KT; Bog M; Kabra M; Simonsen J; Adair M; Jonsson L
Article: NEUROLOGY. 2021;96(17):e2220-e2230
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Xu H; Garcia-Ptacek S; Jonsson L; Wimo A; Nordstrom P; Eriksdotter M
Article: ALZHEIMER’S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS. 2021;7(1):e12189
Identifying relevant outcomes in the progression of Alzheimer's disease; what do patients and care partners want to know about prognosis?
Mank A; van Maurik IS; Bakker ED; van de Glind EMM; Jonsson L; Kramberger MG; Novak P; Diaz A; Gove D; Scheltens P; van der Flier WM; Visser LNC
Journal article: ALZHEIMER'S AND DEMENTIA. 2020;16(S6)
Long‐term treatment with cholinesterase inhibitors in Alzheimer's disease is associated with modest but persisting benefits on cognition and reduced mortality
Eriksdotter M; Xu H; Jönsson L; Wimo A; Nordström P; Garcia‐Ptacek S
Journal article: ALZHEIMER'S AND DEMENTIA. 2020;16(S7)
Informal care time in dementia by cognitive, functional and behavioral disease severity from eight longitudinal cohorts across multiple countries
Handels R; Jönsson L; Green C; Winblad B; Wimo A; Actifcare ID
Article: TRANSLATIONAL PSYCHIATRY. 2020;10(1):364
Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients
Oliver D; Wong CMJ; Bog M; Jonsson L; Kinon BJ; Wehnert A; Jorgensen KT; Irving J; Stahl D; McGuire P; Raket LL; Fusar-Poli P
Article: THE LANCET. HEALTHY LONGEVITY. 2020;1(1):e2-e3
The art of simulation
Wimo A; Handels R; Jonsson L
Article: THE LANCET: DIGITAL HEALTH. 2020;2(5):e229-e239
Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study
Raket LL; Jaskolowski J; Kinon BJ; Brasen JC; Jonsson L; Wehnert A; Fusar-Poli P
Article: ALZHEIMER'S AND DEMENTIA. 2020;16(5):789-796
Controlling for selective dropout in longitudinal dementia data: Application to the SveDem registry
Handels R; Jonsson L; Garcia-Ptacek S; Eriksdotter M; Wimo A
Article: JOURNAL OF ALZHEIMER'S DISEASE. 2020;73(3):967-979
Costs of Inpatient Rehabilitation for Ischemic Stroke in Patients with Dementia: A Cohort Swedish Register-Based Study
Minh TH; Kareholt I; von Euler M; Jonsson L; von Koch L; Eriksdotter M; Garcia-Ptacek S
Article: ALZHEIMER'S AND DEMENTIA. 2019;15(10):1309-1321
Assessing cost-effectiveness of early intervention in Alzheimer's disease: An open-source modeling framework
Green C; Handels R; Gustavsson A; Wimo A; Winblad B; Skoldunger A; Jonsson L
Article: INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH. 2019;28(3):e1778
Identifying and characterizing treatment-resistant schizophrenia in observational database studies
Jonsson L; Simonsen J; Brain C; Kymes S; Watson L
Journal article: ALZHEIMER'S AND DEMENTIA. 2019;15(7S_Part_4):p245
P1‐033: ASSOCIATION WITH REDUCED MORTALITY USING CHOLINESTERASE INHIBITORS IN PATIENTS WITH DEMENTIA: DATA FROM SVEDEM, THE SWEDISH DEMENTIA REGISTRY
Xu H; Garcia-Ptacek S; Jonsson L; Wimo A; Nordström P; Eriksdotter M
Journal article: ALZHEIMER'S AND DEMENTIA. 2019;15(7S_Part_31):p1636
O5‐08‐04: A NEW OPEN‐SOURCE MODELING FRAMEWORK TO ASSESS COST EFFECTIVENESS OF EARLY INTERVENTION IN ALZHEIMER'S DISEASE
Green C; Handels R; Gustavsson A; Wimo A; Skoldunger A; Winblad B; Jonsson L
Journal article: ALZHEIMER'S AND DEMENTIA. 2019;15(7S_Part_31):p1637
O5‐08‐05: STRUCTURAL UNCERTAINTY AND CROSS‐VALIDATION OF DECISION MODELS IN THE AD SETTING: ANSWERING QUESTIONS FROM POLICY MAKERS ON THE RELIABILITY OF HEALTH‐ECONOMIC MODELS
Handels R; Jönsson L; Green C; Eriksdotter M; Qiu C; Winblad B; Wimo A
Article: MULTIPLE SCLEROSIS JOURNAL. 2019;25(5):740-749
The effect of self-assessed fatigue and subjective cognitive impairment on work capacity: The case of multiple sclerosis
Kobelt G; Langdon D; Jonsson L
Article: MULTIPLE SCLEROSIS INTERNATIONAL. 2019;2019:7290285-8
Real-Life Outcome in Multiple Sclerosis in the Czech Republic
Kobelt G; Joensson L; Pavelcova M; Havrdova EK
Article: IEEE REVIEWS IN BIOMEDICAL ENGINEERING. 2019;12:319-332
Technology-Enabled Assessment of Functional Health
Cook DJ; Schmitter-Edgecombe M; Jonsson L; Morant AV
Article: BMC NEUROLOGY. 2017;17(1):213
Inventory of real world data sources in Parkinson's disease
Tanguy A; Joensson L; Ishihara L
Article: ALZHEIMER'S AND DEMENTIA. 2017;13(1):1-7
The worldwide costs of dementia 2015 and comparisons with 2010
Wimo A; Guerchet M; Ali G-C; Wu Y-T; Prina AM; Winblad B; Jonsson L; Liu Z; Prince M
Article: ALZHEIMER'S RESEARCH AND THERAPY. 2016;8(1):59
The societal costs of dementia in Sweden 2012-relevance and methodological challenges in valuing informal care
Wimo A; Jonsson L; Fratiglioni L; Sandman PO; Gustavsson A; Skoldunger A; Johansson L
Article: EUROPEAN JOURNAL OF CANCER CARE. 2016;25(3):466-477
Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study
Jonsson L; Justo N; Musayev A; Krishna A; Burke T; Pellissier J; Judson I; Staddon A; Blay JY
Article: LANCET NEUROLOGY. 2016;15(5):455-532
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Winblad B; Amouyel P; Andrieu S; Ballard C; Brayne C; Brodaty H; Cedazo-Minguez A; Dubois B; Edvardsson D; Feldman H; Fratiglioni L; Frisoni GB; Gauthier S; Georges J; Graff C; Iqbal K; Jessen F; Johansson G; Jonsson L; Kivipelto M; Knapp M; Mangialasche F; Melis R; Nordberg A; Rikkert MO; Qiu C; Sakmar TP; Scheltens P; Schneider LS; Sperling R; Tjernberg LO; Waldemar G; Wimo A; Zetterberg H
Article: VALUE IN HEALTH. 2014;17(6):707-713
Analyzing Overall Survival in Randomized Controlled Trials with Crossover and Implications for Economic Evaluation
Jonsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jonsson B; Weinstein MC; Drummond M
Article: JOURNAL OF INTERNAL MEDICINE. 2014;275(3):304-316
Health economic evaluation of treatments for Alzheimer's disease: impact of new diagnostic criteria
Wimo A; Ballard C; Brayne C; Gauthier S; Handels R; Jones RW; Jonsson L; Khachaturian AS; Kramberger M
Article: CANCER MANAGEMENT AND RESEARCH. 2014;6:365-371
Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study
Tang Y; Bycott P; Akerborg O; Jonsson L; Negrier S; Chen C
Article: LUPUS. 2013;22(8):793-801
Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports
Bexelius C; Wachtmeister K; Skare P; Jonsson L; van Vollenhoven R
Article: ALZHEIMER'S AND DEMENTIA. 2013;9(4):429-435.e17
Application of Resource Utilization in Dementia (RUD) instrument in a global setting
Wimo A; Gustavsson A; Jonsson L; Winblad B; Hsu M-A; Gannon B
Journal article: ALZHEIMER'S AND DEMENTIA. 2013;9(4S_Part_11):p467
P2–298: Assessing the economic value of potential disease‐modifying agents in Alzheimer's disease using simulation
Getsios D; Guo S; Revankar N; Jonsson L; Neumann P; Thompson G; Bobula J; Lacey L; Gaudig M
Journal article: ANNALS OF THE RHEUMATIC DISEASES. 2013;72(Suppl 3):a477-A478
FRI0306 Costs and working capacity among patients with systemic lupus erythematosus (SLE) in working-age (18-64 years)
Bexelius C; Wachtmeister K; Skare P; Jönsson L; van Vollenhoven RF
Article: BMC HEALTH SERVICES RESEARCH. 2013;13:173
Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece
Maniadakis N; Kourlaba G; Mougiakos T; Chatzimanolis I; Jonsson L
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2013;28(5):454-462
Costs explained by function rather than diagnosis-results from the SNAC Nordanstig elderly cohort in Sweden
Lindholm C; Gustavsson A; Jonsson L; Wimo A
Article: ALZHEIMER'S AND DEMENTIA. 2013;9(1):1-11.e3
The worldwide economic impact of dementia 2010
Wimo A; Jonsson L; Bond J; Prince M; Winblad B
Article: ARCHIVES OF OSTEOPOROSIS. 2013;8(1-2):144
SCOPE: a scorecard for osteoporosis in Europe
Kanis JA; Borgstrom F; Compston J; Dreinhoefer K; Nolte E; Jonsson L; Lems WF; McCloskey EV; Rizzoli R; Stenmark J
Journal article: VALUE IN HEALTH. 2012;15(7):a422
PCN75 Survival and Costs in Metastatic Renal Cell Carcinoma: A Comparison of mRCC Treatment Pre- and Post Tyrosine Kinase Inhibitor (TKI) Introduction Using Retrospective Registry Data
Jönsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandström P; Ljungberg B; Jakobsson M
Journal article: VALUE IN HEALTH. 2012;15(7):a464
PRM24 Methods for Analysis of Censored Cost Data
Jönsson L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2012;13(5):561-568
Disease progression and costs of care in Alzheimer's disease patients treated with donepezil: a longitudinal naturalistic cohort
Gustavsson A; Jonsson L; Parmler J; Andreasen N; Wattmo C; Wallin AK; Minthon L
Article: ANNALS OF ONCOLOGY. 2012;23(10):2763-2770
Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study
Leahy M; Garcia del Muro X; Reichardt P; Judson I; Staddon A; Verweij J; Baffoe-Bonnie A; Jonsson L; Musayev A; Justo N; Burke T; Blay JY
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2012;19(1):155-162
The economic cost of brain disorders in Europe
Olesen J; Gustavsson A; Svensson M; Wittchen H-U; Jonsson B
Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2011;21(10):718-779
Cost of disorders of the brain in Europe 2010
Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jonsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen H-C; Stovner LJ; Vallat J-M; Van den Bergh P; van Os J; Vos P; Xu W; Wittchen H-U; Jonsson B; Olesen J
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2011;26(8):825-832
The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project
Wimo A; Jonsson L; Gustavsson A; McDaid D; Ersek K; Georges J; Gulacsi L; Karpati K; Kenigsberg P; Valtonen H
Article: ALZHEIMER'S AND DEMENTIA. 2011;7(4):466-473
Costs of care in a mild-to-moderate Alzheimer clinical trial sample: Key resources and their determinants
Gustavsson A; Cattelin F; Jonsson L
Article: ALZHEIMER'S AND DEMENTIA. 2011;7(3):318-327
Predictors of costs of care in Alzheimer's disease: A multinational sample of 1222 patients
Gustavsson A; Brinck P; Bergvall N; Kolasa K; Wimo A; Winblad B; Jonsson L
Article: INTERNATIONAL PSYCHOGERIATRICS. 2011;23(1):73-85
Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease
Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jonsson L
Article: NEUROLOGY. 2010;75(14):1256-1262
Assessment of potential measures in models of progression in Alzheimer disease
McLaughlin T; Buxton M; Mittendorf T; Redekop W; Mucha L; Darba J; Jonsson L; Lacey L; Leibman C
Article: JOURNAL OF NUTRITION, HEALTH AND AGING. 2010;14(8):685-690
The resource utilization in dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia
Wimo A; Jonsson L; Zbrozek A
Article: JOURNAL OF NUTRITION, HEALTH AND AGING. 2010;14(8):648-654
Differences in resource use and costs of dementia care between European countries: Baseline data from the ictus study
Gustavsson A; Jonsson L; Rapp T; Reynish E; Ousset PJ; Andrieu S; Cantet C; Winblad B; Vellas B; Wimo A
Article: JOURNAL OF NUTRITION, HEALTH AND AGING. 2010;14(8):633-639
Costs of dementia in Hungary
Ersek K; Kovacs T; Wimo A; Karpati K; Brodszky V; Pentek M; Joensson L; Gustavsson A; Mcdaid D; Kenigsberg PA; Valtonen H; Gulacsi L
Journal article: ALZHEIMER'S AND DEMENTIA. 2010;6(4S_Part_12):s373
P2‐202: Dementia work‐up is more costly in men than in women
Religa D; Spangberg K; Wimo A; Jonsson L; Edlund A-K; Winblad B; Eriksdotter-Jonhagen M
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2010;25(6):622-632
Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer's disease
Gustavsson A; Jonsson L; McShane R; Boada M; Wimo A; Zbrozek AS
Article: CURRENT ALZHEIMER RESEARCH. 2010;7(4):358-367
Cross Sectional Observational Study on the Societal Costs of Alzheimer's Disease
Mesterton J; Wimo A; By A; Langworth S; Winblad B; Jonsson L
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2010;25(5):476-482
The cost of diagnosing dementia in a community setting
Jedenius E; Wimo A; Stromqvist J; Jonsson L; Andreasen N
Article: JOURNAL OF NUTRITION, HEALTH AND AGING. 2010;14(5):358-360
IPECAD5-Fifth International Pharmaco-Economic Conference on Alzheimer's Disease
Gustavsson A; Jonsson L; Fillit H; Johansson G; Wimo A; Winblad B
Article: ALZHEIMER'S AND DEMENTIA. 2010;6(2):98-103
The worldwide societal costs of dementia: Estimates for 2009
Wimo A; Winblad B; Jonsson L
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2010;8(5):317-325
Cost of illness and drivers of cost in atrial fibrillation in Sweden and Germany.
Jönsson L; Eliasson A; Kindblom J; Almgren O; Edvardsson N
Article: INFLAMMATORY BOWEL DISEASES. 2009;15(12):1882-1890
Resource Use and Societal Costs for Crohn's Disease in Sweden
Mesterton J; Jonsson L; Almer SHC; Befrits R; Friis-Liby I; Lindgren S
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2009;24(10):1072-1078
Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies
Gustavsson A; Van der Putt R; Jonsson L; McShane R
Journal article: JOURNAL OF NUTRITION, HEALTH AND AGING. 2009
IPECAD5 — Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease
Gustavsson A; Jonsson L; Fillit H; Johansson G; Wimo A; Winblad B
Journal article: GERONTOLOGIE ET SOCIETE. 2009;vol. 32 / n° 128-129(1):297-318
Impact socio-économique de la maladie d'Alzheimer et des maladies apparentées en Europe
Kenigsberg P-A; Ersek K; Gulácsi L; Karpati K; Jacques A; Gustavsson A; Jönsson L; Mcdaid D; Valtonen H; Wimo A
Journal article: ALZHEIMER'S AND DEMENTIA. 2009;5(4S_Part_13):p410
P3‐228: Trends in informal care in Sweden: Is it decreasing? Cross‐sectional studies with the RUD instrument
Wimo A; Wimo A; Sjolund B; Jönsson L; Skoldunger A; Winblad B
Article: EUROPEAN RADIOLOGY. 2009;19:S753-S763
Health-economic evaluation of three imaging strategies in patients with suspected colorectal liver metastases: Gd-EOB-DTPA-enhanced MRI vs. extracellular contrast media-enhanced MRI and 3-phase MDCT in Germany, Italy and Sweden
Zech CJ; Grazioli L; Jonas E; Ekman M; Niebecker R; Gschwend S; Breuer J; Jonsson L; Kienbaum S
Article: LAKARTIDNINGEN. 2009;106(18-19):1277-1282
[Prevalence study of societal costs for dementia 2000-2005. More demented people--but somewhat reduced costs per person].
Wimo A; Johansson L; Jönsson L
Journal article: ALZHEIMER'S AND DEMENTIA. 2008;4(4S_Part_20):t661
P3‐476: Willingness to pay for reductions in care need: Estimating the value of informal care
Gustavsson A; Jönsson L; Zbrozek AS
Article: THE BMJ. 2008;336(7636):134-138
Community occupational therapy for older patients with dementia and their care givers:: cost effectiveness study
Graff MJL; Adang EMM; Vernooij-Dassen MJM; Dekker J; Jonsson L; Thijssen M; Hoefnagels WHL; Rikkert MGMO
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2007;61(8):1410-1414
Determinants of cholesterol goal attainment at 12 months in patients with hypercholesterolaemia not at consensus goal after 3 months of treatment with lipid-lowering drugs
Lindgren P; Borgstrom F; Stalhammar J; Alemao E; Jonsson L
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2007;22(7):649-655
Health utilities in mild cognitive impairment and dementia:: a population study in Sweden
Ekman M; Berg J; Wimo A; Jonsson L; McBurney C
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2007;22(7):639-648
Time use and costs of institutionalised elderly persons with or without dementia:: results from the Nordanstig cohort in the Kungsholmen Project -: a population based study in Sweden
Nordberg G; Wimo A; Jonsson L; Kareholt I; Sjolund B-M; Lagergren M; von Strauss E
Journal article: ALZHEIMER'S AND DEMENTIA. 2007;3(3S_Part_2):s146
P‐148: The resource utilization in dementia (RUD) instrument is valid to assess informal care time in dementia
Wimo A; Jönsson L; Zbrozek AS
Journal article: ALZHEIMER'S AND DEMENTIA. 2007;3(3S_Part_3):s165
S1–01–01: Public health impact
Winblad B; Wimo A; Jonsson L
Article: ALZHEIMER'S AND DEMENTIA. 2007;3(2):81-91
An estimate of the total worldwide societal costs of dementia in 2005
Wimo A; Winblad B; Jonsson L
Article: ALZHEIMER DISEASE AND ASSOCIATED DISORDERS. 2007;21(2):150-154
Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease
Bostrom F; Jonsson L; Minthon L; Londos E
Article: BREAST CANCER RESEARCH AND TREATMENT. 2007;102(3):289-299
Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden
Lundkvist J; Wilking N; Holmberg S; Jonsson L
Article: NEUROEPIDEMIOLOGY. 2007;29(1-2):29-38
The ICTUS study:: A prospective longitudinal observational study of 1,380 AD patients in Europe -: Study design and baseline characteristics of the cohort
Reynish E; Cortes F; Andrieu S; Cantet C; Rikkert MO; Melis R; Froelich L; Frisoni GB; Joensson L; Visser PJ; Ousset PJ; Vellas B
Journal article: ALZHEIMER'S AND DEMENTIA. 2006;2(3S_Part_1):s19-s20
O1–05–08: The worldwide directs costs and costs of informal care of dementia
Winblad B; Wimo A; Jönsson L
Article: VALUE IN HEALTH. 2006;9(3):193-198
Cost of hypoglycemia in patients with type 2 diabetes in Sweden
Jönsson L; Bolinder B; Lundkvist J
Article: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2006;21(5):449-459
Determinants of costs of care for patients with Alzheimer's disease
Jonsson L; Jonhagen ME; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
Article: AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS. 2006;6(2):121-128
Lipid management and cholesterol goal attainment in Norway.
Ose L; Skjeldestad FE; Bakken IJ; Levorsen A; Alemao EA; Yin DD; Borgström F; Jönsson L
Article: DEMENTIA AND GERIATRIC COGNITIVE DISORDERS. 2006;21(3):175-181
An estimate of the worldwide prevalence and direct costs of dementia in 2003
Wimo A; Jonsson L; Winblad B
Article: ALZHEIMER DISEASE AND ASSOCIATED DISORDERS. 2006;20(1):49-55
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL
Jönsson L; Andreasen N; Kilander L; Soininen H; Waldemar G; Nygaard H; Winblad B; Jönhagen ME; Hallikainen M; Wimo A
Article: JOURNAL OF CARDIOVASCULAR RISK. 2005;12(6):530-534
Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice
Lindgren P; Borgström F; Stålhammar J; Alemao E; Yin DDP; Jönsson L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2005;6(3):197-202
The economic and quality of life impact of hypoglycemia.
Lundkvist J; Berne C; Bolinder B; Jönsson L
Journal article: JOURNAL OF HUMAN HYPERTENSION. 2005;19(8):662
The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke:: results from the Study on COgnition and Prognosis in the Elderly (vol 19, pg 569, 2005)
Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
Article: SPINE. 2005;30(15):1777-1785
Burden of illness of chronic low back pain in Sweden a cross-sectional, retrospective study in primary care setting
Ekman M; Jönhagen S; Hunsche E; Jönsson L
Article: JOURNAL OF HUMAN HYPERTENSION. 2005;19(7):569-576
The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke:: results from the Study on COgnition and Prognosis in the Elderly
Lundkvist J; Ekman M; Kartman B; Carlsson J; Jönsson L; Lithell H
Journal article: ALZHEIMER'S AND DEMENTIA. 2005;1(1S_Part_3):s101
[O2‐04‐01]: The worldwide costs of dementia
Winblad B; Jönsson L; Wimo A
Article: AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY. 2005;3(2):77-86
Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:50-53
Cost of dementia in Europe
Jönsson L; Berr C
Article: ALLERGY. EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2005;60(3):338-342
Association between allergic rhinitis and hospital resource use among asthmatic children in Norway
Kocevar VS; Thomas J; Jonsson L; Valovirta E; Kristensen F; Yin DD; Bisgaard H
Journal article: JOURNAL OF MEDICAL ECONOMICS. 2005;8(1-4):131-138
Cost-effective prevention of renal failure in type 2 diabetics using losartan
Jönsson L; Carides GW; Burke TA; Brandt A-SI; Salonen T; Schön S; Weiss L
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2004;5 Suppl 1:S30-S35
Economic evidence in dementia: a review.
Jönsson L
Article: RHEUMATOLOGY. 2004;43(9):1158-1166
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®)
Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
Article: CHEST. 2004;125(5):1680-1684
Variations in pediatric asthma hospitalization rates and costs between and within Nordic countries
Kocevar VS; Bisgaard H; Jönsson L; Valovirta E; Kristensen F; Yin DD; Thomas J
Journal article: ATHEROSCLEROSIS PLUS. 2004;5(1):141
M.607 Current management of hyperlipidemia in Norway and factors associated with cholesterol goal attainment
Ose L; Skjeldestad F; Bakken I; Levorsen A; Alemao E; Yin D; Borgström F; Jönsson L
Article: PHARMACOECONOMICS (AUCKLAND). 2004;22:25-35
Cost of care for patients treated with lipid-lowering drugs
Carlsson Å; Borgström F; Stålhammar J; Alemao E; Yin D; Jönsson L
Article: UGESKRIFT FOR LAEGER. 2003;165(43):4112-4116
[Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].
Jönsson L; Borgström F; Zethraeus N
Article: HERNIA : THE JOURNAL OF HERNIAS AND ABDOMINAL WALL SURGERY. 2003;7(3):114-117
Cost analysis of incisional hernia repair by suture or mesh.
Israelsson LA; Jönsson L; Wimo A
Journal article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2003;4(1):50-59
Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Fredrikson S
Article: RHEUMATOLOGY. 2003;42(2):326-335
The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study
Kobelt G; Jönsson L; Young A; Eberhardt K
Article: PHARMACOECONOMICS (AUCKLAND). 2003;21(5):305-314
Cost effectiveness of alendronate (Fosamax®) for the treatment of osteoporosis and prevention of fractures
Johnell O; Jönsson B; Jönsson L; Black D
Article: ARTHRITIS & RHEUMATOLOGY. 2002;46(9):2310-2319
Modeling the progression of rheumatoid arthritis -: A two-country model to estimate costs and consequences of rheumatoid arthritis
Kobelt G; Jönsson L; Lindgren P; Young A; Eberhardt K
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2002;18(1):127-138
Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data
Kobelt G; Jönsson L; Miltenburger C
Article: BLOOD PRESSURE. 2002;11(1):46-52
The potential economic consequences of cognitive improvement with losartan
Jönsson L; Gerth W; Fastbom J
Article: LAKARTIDNINGEN. 2001;98(38):4042-4048
Can the cost of future health care and social services needs of the elderly be calculated?
Wimo A; Jönsson L
Article: DERMATOLOGY. 2001;202(1):38-43
Pharmacoeconomic evaluation of calcipotriol (Daivonex®/Dovonex®) and UVB phototherapy in the treatment of psoriasis:: A Markov model for the Netherlands
de Rie MA; de Hoop D; Jönsson L; Bakkers EJM; Sorensen M
Journal article: VALUE IN HEALTH. 2000;3(5):376
PHDE4: PHARMACOECONOMIC EVALUATION OF CALCIPOTRIOL AND UVB IN THE TREATMENT OF PSORIASIS IN THE NETHERLANDS
de Rie M; de Hoop D; Jonsson L; Bakkers E; Sorensen M
Article: ALZHEIMER DISEASE AND ASSOCIATED DISORDERS. 2000;14(3):137-140
Second International Pharmacoeconomic Conference on Alzheimer's Disease
Jönsson L; Jönsson B; Wimo K; Whitehouse P; Winblad B
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2000;16(3):768-780
Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis
Kobelt G; Jönsson L; Henriksson F; Fredrikson S; Jönsson B
Article: PHARMACOECONOMICS (AUCKLAND). 1999;16(4):409-416
Costs of mini mental state examination-related cognitive impairment
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Journal article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 1999;9:289
A cost-effectiveness clinical decision analysis for schizophrenia: Results from Sweden
Wieselgren I-M; Lindström E; Lindström L; Jönsson L
Article: CLINICAL THERAPEUTICS. 1999;21(7):1230-1240
The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease:: A Markov model
Jönsson L; Lindgren P; Wimo A; Jönsson B; Winblad B
Article: ARTHRITIS & RHEUMATOLOGY. 1999;42(2):347-356
Economic consequences of the progression of rheumatoid arthritis in Sweden
Kobelt G; Eberhardt K; Jönsson L; Jönsson B
Article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 1999;15(1):207-219
Modeling cost of treatment with new topical treatments for glaucoma -: Results from France and the United Kingdom
Kobelt G; Jönsson L
Article: GRAEFE'S ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY. 1998;236(11):811-821
Direct costs of glaucoma management following initiation of medical therapy - A simulation model based on an observational study of glaucoma treatment in Germany
Kobelt G; Jonsson L; Gerdtham U; Krieglstein GK
Article: NEUROUROLOGY AND URODYNAMICS. 1998;17(6):599-611
Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model
Kobelt G; Jonsson L; Mattiasson A
Show more

All other publications

Review: ALZHEIMER'S AND DEMENTIA. 2024;20(6):4290-4314
The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact
Kalaria R; Maestre G; Mahinrad S; Acosta DM; Akinyemi RO; Alladi S; Allegri RF; Arshad F; Babalola DO; Baiyewu O; Bak TH; Bellaj T; Brodie-Mends DK; Carrillo MC; Celestin K-K; Damasceno A; de Silva RK; de Silva R; Djibuti M; Dreyer AJ; Ellajosyula R; Farombi TH; Friedland RP; Garza N; Gbessemehlan A; Georgiou EE-Z; Govia I; Grinberg LT; Guerchet M; Gugssa SA; Gumikiriza-Onoria JL; Hogervorst E; Hornberger M; Ibanez A; Ihara M; Issac TG; Joensson L; Karanja WM; Lee JH; Leroi I; Livingston G; Manes FF; Mbakile-Mahlanza L; Miller BL; Musyimi CW; Mutiso VN; Nakasujja N; Ndetei DM; Nightingale S; Novotni G; Nyamayaro P; Nyame S; Ogeng'o JA; Ogunniyi A; de Oliveira MO; Okubadejo NU; Orrell M; Paddick S-M; Pericak-Vance MA; Pirtosek Z; Potocnik FCV; Raman R; Rizig M; Rosselli M; Salokhiddinov M; Satizabal CL; Sepulveda-Falla D; Seshadri S; Sexton CE; Skoog I; George-Hyslop PHS; Suemoto CK; Thapa P; Udeh-Momoh CT; Valcour V; Vance JM; Varghese M; Vera JH; Walker RW; Zetterberg H; Zewde YZ; Ismail O
Review: JOURNAL OF INTERNAL MEDICINE. 2024;295(3):281-291
People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare
Wahlberg K; Winblad B; Cole A; Herring WL; Ramsberg J; Torontali I; Visser P-J; Wimo A; Wollaert L; Jonsson L
Preprint: MEDRXIV. 2024
Generate Synthetic Data in R for a Hypothetical Alzheimer’s Disease Trial
Handels R; Jönsson L; Raket LL; Initiative TADN
Conference publication: VALUE IN HEALTH. 2023;26(12):s1
P3 Open-Source Model Framework for Health-Economic Evaluation of Early Treatment in Alzheimer's Disease
Handels R; Wimo A; Skoldunger A; Tate A; Winblad B; Silvertand D; Nguyen L; Jönsson L; Grimm S; Aye S; Herring W
Conference publication: ANNALS OF ONCOLOGY. 2023;34:s833-s834
Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Kim K; Sweeting M; Wilking N; Jonsson L
Letter: ALZHEIMER'S AND DEMENTIA. 2023;19(10):4760-4763
Response to "Comment on 'Dementia prevention: The potential long-term cost-effectiveness of the FINGER prevention program'"
Wimo A; Handels R; Antikainen R; Eriksdotter M; Jonsson L; Knapp M; Kulmala J; Laatikainen T; Lehtisalo J; Peltonen M; Skoldunger A; Soininen H; Solomon A; Strandberg T T; Tuomilehto J; Ngandu T; Kivipelto M
Conference publication: NEUROLOGY. 2023;100(17)
Patient-identified most bothersome symptom as a driver of health-related quality of life experienced by patients with migraine
Jonsson L; Awad SF; Regnier SA; Talon B; Kymes S; Lee XY; Goadsby PJ
Conference publication: NEUROLOGY. 2023;100(17)
Effect of Eptinezumab on Utility Scores in Patients with Migraine: Results from the DELIVER Study
Jonsson L; Regnier SA; Kymes S; Talon B; Awad SF; Lee XY; Goadsby PJ
Editorial comment: ALZHEIMER'S AND DEMENTIA. 2023;19(3):1105-1108
The Nairobi Declaration-Reducing the burden of dementia in low- and middle-income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs
Maestre G; Carrillo M; Kalaria R; Acosta D; Adams L; Adoukonou T; Akinwande K; Akinyemi J; Akinyemi R; Akpa O; Alladi S; Allegri R; Arizaga R; Arshad F; Arulogun O; Ndetei D; Baiyewu O; Issac T; Bellaj T; Boshe J; Brayne C; Brodie-Mends D; Brown R; Cahn J; Cyrille N; Damasceno A; de Silva R; de Silva R; Djibuti M; Dreyer AJ; Ellajosyula R; Farombi T; Fongang B; Forner S; Friedland R; Garza N; Gbessemehlan A; Georgiou EE-Z; Gouider R; Govia I; Grinberg L; Guerchet M; Gugssa S; Gumikiriza-Onoria JL; Gustafson D; Hogervorst E; Hornberger M; Ibanez A; Ihara M; Ismail O; Issac T; Joensson L; Kaputu C; Karanja W; Karungi J; Tshala-Katumbay D; Kunkle B; Lee JH; Leroi I; Lewis R; Livingston G; Lopera F; Lwere K; Manes F; Mbakile-Mahlanza L; Mena P; Miller B; Millogo A; Mohamed A; Musyimi C; Mutiso V; Nakasujja N; Ndetei D; Nightingale S; Njamnshi AK; Novotni G; Nyamayaro P; Nyame S; Ogeng'o J; Ogunniyi A; De Oliveira MO; Okubadejo N; Orrell M; Orunmuyi A; Owolabi M; Paddick S; Pericak-Vance MA; Pirtosek Z; Potocnik F; Preston B; Raman R; Ranchod K; Rizig M; Rosselli M; Deepa R; Roy U; Salokhiddinov M; Sano M; Sarfo F; Satizabal CL; Sepulveda-Falla D; Seshadri S; Sexton C; Skoog I; St George-Hyslop P; Suemoto C; Tanner J; Thapa P; Toure K; Ucheagwu V; Udeh-Momoh C; Valcour V; Vance J; Varghese M; Vera J; Walker R; Weidner W; Sebastian W; Gay PW; Zetterberg H; Zewde Y
Preprint: MEDRXIV. 2023
Potential cost-effectiveness of individualized medicine in prodromal Alzheimer’s disease by demographic, clinical and cerebrospinal fluid proteomics factors
Handels R; Wesenhagen K; Tijms B; Teunissen C; Visser PJ; Jönsson L
Review: PHARMACOECONOMICS (AUCKLAND). 2023;41(1):59-75
The Costs of Dementia in Europe: An Updated Review and Meta-analysis
Jonsson L; Tate A; Frisell O; Wimo A
Editorial comment: THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE. 2023;10(3):349-352
Amyloid-targeting New Therapies for Alzheimer's Disease: A Health Economics Perspective
Jonsson L; Wimo A
Editorial comment: THE LANCET REGIONAL HEALTH. EUROPE. 2022;20:100472
The personal economic burden of dementia in Europe Comment
Jonsson L
Conference publication: VALUE IN HEALTH. 2022;25(12):S390
DISEASE-SPECIFIC QUALITY-OF-LIFE MEASURES MAPPED TO THE EQ-5D IN A CHRONIC DISORDER WITH RECURRENT ATTACKS: ANALYSIS OF THE DELIVER TRIAL IN PATIENTS WITH MIGRAINE
Jonsson L; Regnier SA; Kymes S; Awad SF; Talon B; Lee XY; Goadsby PJ
Conference publication: VALUE IN HEALTH. 2022;25(12):S436
EFFECT OF EPTINEZUMAB ON UTILITY SCORES IN PATIENTS WITH MIGRAINE: RESULTS FROM THE DELIVER STUDY
Jonsson L; Regnier SA; Kymes S; Talon B; Awad SF; Lee XY; Goadsby PJ
Conference publication: VALUE IN HEALTH. 2022;25(12):S483
EFFECT OF MORTALITY ON COST-EFFECTIVENESS MODELING OF DISEASE-MODIFYING TREATMENT FOR ALZHEIMER'S DISEASE
Aye S; Jonsson L
Conference publication: VALUE IN HEALTH. 2022;25(12):S31-S32
PREDICTING SOJOURN TIMES BY DEMENTIA STAGES: EVIDENCE FROM 76,747 PATIENTS IN THE SWEDISH NATIONAL REGISTRY FOR COGNITIVE DISORDERS (SVEDEM)
Tate A; Jonsson L
Preprint: RESEARCH SQUARE. 2020
Prognosis of Alzheimer’s disease; what do patients and care partners want to know?
Mank A; Maurik IV; Bakker E; Glind EMMVD; Jönsson L; Kramberger M; Novak P; Diaz A; Gove D; Scheltens P; Flier WVD; Visser LNC
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:302
How different regulatory systems recognize and reward pharmaceutical innovation - a comparative analysis of intelectual property (IP) protection, marketing authorization and pricing/reimbursement systems with a focus on oncology
Justo N; Jonsson L; Wilking N
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2019;26:745-746
Costs of stroke rehabilitation in patients with dementia: a Swedish register-based study
Hoang MT; Kareholt I; Von Euler M; Jonsson L; Von Koch L; Eriksdotter M; Garcia-Ptacek S
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:571
Real-world outcome in multiple sclerosis estimated from two cost of illness studies and MS clinic data in the Czech Republic
Kobelt G; Jonsson L; Pavelkova M; Kubala EH
Editorial comment: ALZHEIMER'S AND DEMENTIA. 2017;13(3):201-204
Special topic section on health economics and public policy of Alzheimer's disease
Jonsson L; Lin P-J; Khachaturian AS
Corrigendum: ALZHEIMER'S RESEARCH AND THERAPY. 2017;9(1):12
The societal costs of dementia in Sweden 2012 - relevance and methodological challenges in valuing informal care (vol 8, 59, 2016)
Wimo A; Jonsson L; Fratiglioni L; Sandman PO; Gustavsson A; Skoldunger A; Johansson JL
Conference publication: VALUE IN HEALTH. 2016;19(7):A524
ESTIMATING THE ECONOMIC BURDEN ASSOCIATED WITH THE EARLY STAGES OF PROGRESSION OF ALZHEIMER'S DISEASE IN EUROPE
Lindgren P; Jonsson L; Coste F; Chan E; Bosshard R
Conference publication: VALUE IN HEALTH. 2013;16(7):A611
STRUCTURAL FAILURE TIME MODELING OF OVERALL SURVIVAL EFFECTS IN ONCOLOGY TRIALS WITH SUBSEQUENT THERAPIES
Jonsson L; Fleischer F; Bluhmki E; Griebsch I
Conference publication: VALUE IN HEALTH. 2013;16(7):A610
EVALUATING OVERALL SURVIVAL IN ONCOLOGY TRIALS WITH SUBSEQUENT THERAPIES: A METHODOLOGICAL REVIEW AND APPLICATION IN NON-SMALL CELL LUNG CANCER
Jonsson L; Fleischer F; Bluhmki E; Griebsch I
Conference publication: ANNALS OF THE RHEUMATIC DISEASES. 2013;72:477-478
COSTS AND WORKING CAPACITY AMONG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN WORKING-AGE (18-64 YEARS)
Bexelius C; Wachtmeister K; Skare P; Jonsson L; van Vollenhoven RF
Conference publication: VALUE IN HEALTH. 2012;15(7):A317
PROPOSED AND ACTUAL BUREAUCRATIC BURDEN OF HTA SUBMISSIONS TO THE INDUSTRY-CASE STUDIES FROM GERMANY AND UK
Schweikert B; Jonsson L
Corrigendum: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2012;22(3):237-238
Cost of disorders of the brain in Europe 2010 (vol 21, pg 718, 2011)
Gustavsson A; Svensson M; Jacobi F; Allgulander C; Alonso J; Beghi E; Dodel R; Ekman M; Faravelli C; Fratiglioni L; Gannon B; Jones DH; Jennum P; Jordanova A; Jonsson L; Karampampa K; Knapp M; Kobelt G; Kurth T; Lieb R; Linde M; Ljungcrantz C; Maercker A; Melin B; Moscarelli M; Musayev A; Norwood F; Preisig M; Pugliatti M; Rehm J; Salvador-Carulla L; Schlehofer B; Simon R; Steinhausen H-C; Stovner LJ; Vallat J-M; Van den Bergh P; van Os J; Vos PE; Xu W; Wittchen H-U; Jonsson B; Olesen J
Conference publication: VALUE IN HEALTH. 2012;15(7):A464
METHODS FOR ANALYSIS OF CENSORED COST DATA
Jonsson L
Conference publication: VALUE IN HEALTH. 2012;15(7):A422
SURVIVAL AND COSTS IN METASTATIC RENAL CELL CARCINOMA: A COMPARISON OF MRCC TREATMENT PRE- AND POST TYROSINE KINASE INHIBITOR (TKI) INTRODUCTION USING RETROSPECTIVE REGISTRY DATA
Jonsson L; Sandin R; Lindgren P; Kowalski J; Wahlgren T; Harmenberg U; Sandstrom P; Ljungberg B; Jakobsson M
Conference publication: VALUE IN HEALTH. 2011;14(7):A289
MORTALITY IN RELATION TO DISEASE SEVERITY IN SUBJECTS WITH DEMENTIA
Jonsson L; Fratiglioni L; Wimo A
Conference publication: EUROPEAN JOURNAL OF CANCER. 2011;47:S663
Chemotherapy Treatment Patterns in Patients With Metastatic Soft Tissue Sarcoma - the Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study
Leahy M; del Muro X; Pisters P; Reichardt P; Jonsson L; Eriksson J; Baffoe-Bonnie A; Burke T; Blay JY
Meeting abstract: VALUE IN HEALTH. 2010;13(7):A282
EXTRAPOLATION IN TRIAL-BASED COST-EFFECTIVENESS MODELING: IN SEARCH OF A STANDARD
Ekman M; Charbonneau C; Ramsberg J; Jonsson L; Sandin R; Jonsson B; Drummond M; Weinstein MC
Meeting abstract: VALUE IN HEALTH. 2010;13(7):A246
ANALYZING OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS WITH CROSS-OVER
Jonsson L; Sandin R; Ekman M; Ramsberg J; Charbonneau C; Huang X; Jonsson B; Weinstein MC; Drummond M
Conference publication: ANNALS OF ONCOLOGY. 2010;21:414-415
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC SARCOMA - THE SARCOMA TREATMENT AND BURDEN OF ILLNESS STUDY IN NORTH AMERICA AND EUROPE (SABINE) STUDY
Leahy M; Reichardt P; Del Muro XG; Pisters P; Chawla S; Martin J; Jonsson L; Eriksson J; Burke T; Blay J-Y
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2010;17:75
Age affects quality and cost of dementia diagnosis
Religa D; Spangberg K; Wimo A; Jonsson L; Edlund A-K; Winblad B; Jonhagen ME
Conference publication: VALUE IN HEALTH. 2009;12(7):A369
COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN
Mesterton J; By A; Sandelin R; Jonsson L
Conference publication: VALUE IN HEALTH. 2009;12(7):A361
A PATIENT PERSPECTIVE ON SIDE EFFECTS OF ANTIPSYCHOTIC THERAPY: THE TOOL INSTRUMENT
Lindstrom E; Jonsson L; Berntsson A
Conference publication: VALUE IN HEALTH. 2009;12(7):A361-A362
TOOL: MULTI-ATTRIBUTE UTILITY FUNCTION REFLECTING PATIENT EXPERIENCE OF SIDE EFFECTS TO ANTIPSYCHOTIC THERAPY
Jonsson L; Lang A; Lindstrom E
Meeting abstract: VALUE IN HEALTH. 2009;12(3):A176
ECONOMIC EVALUATION OF AGOMELATINE FOR MAJOR DEPRESSIVE DISORDER IN SWEDEN
Clapham E; Berg J; Ekman M; Jonsson L
Review: JOURNAL OF ALZHEIMER'S DISEASE. 2009;16(2):235-270
Methodological Issues in Primary Prevention Trials for Neurodegenerative Dementia
Andrieu S; Coley N; Aisen P; Carrillo MC; DeKosky S; Durga J; Fillit H; Frisoni GB; Froelich L; Gauthier S; Jones R; Jonsson L; Khachaturian Z; Morris JC; Orgogozo J-M; Ousset P-J; Robert P; Salmon E; Sampaio C; Verhey F; Wilcock G; Vellas B
Conference publication: JOURNAL OF MENTAL HEALTH POLICY AND ECONOMICS. 2009;12:S28
Adherence to Initial Antidepressant Therapy is Associated with Lower Resource Use and Higher Health Utility in a Longitudinal Survey of Patients with Depression in Sweden
Marteau F; Despiegel N; Jonsson L
Preprint: SSRN ELECTRONIC JOURNAL. 2009
Why Should Economic Evaluations of Medical Innovations Have a Societal Perspective?
Johannesson M; Jonsson B; Jonsson L; Kobelt G; Zethraeus N
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2009;16:358
The lower cost of dementia diagnosis in women
Religa D; Spangberg K; Wimo A; Jonsson L; Edlund A-K; Johansson N; Winblad B; Eriksdotter MJ
Review: PHARMACOECONOMICS (AUCKLAND). 2009;27(5):391-403
The Cost of Dementia in Europe A Review of the Evidence, and Methodological Considerations
Jonsson L; Wimo A
Meeting abstract: VALUE IN HEALTH. 2008;11(6):A423-A424
COST OF INSOMNIA IN PATIENTS OVER 54YEARS IN SWEDEN
Justo N; Jonsson L; Ekman M; Berg J
Conference publication: VALUE IN HEALTH. 2007;10(6):A387
Mild to moderate Alzheimer's disease associated with significanttime burden to caregivers
Jonsson L; Grundman M; Black R; Liu E; Minassian S; Zbrozek A; Leibman C; Lucas C; McLaughlin T
Review: INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY. 2007;22(8):713-719
Patients with Lewy body dementia use more resources than those with Alzheimer's disease
Bostrom F; Jonsson L; Minthon L; Londos E
Published conference paper: JOURNAL OF NUTRITION, HEALTH AND AGING. 2007;11(4):353-355
Assessing health economic outcome in Alzheimer's disease clinical trials
Jonsson L
Meeting abstract: VALUE IN HEALTH. 2007;10(3):A83
A multi-domain micro-simulation economic modeling framework in Alzheimer's disease
Jonsson L; Gustavsson A; Ganguly R
Conference publication: VALUE IN HEALTH. 2007;10(3):A82
Disease progression in Alzheimer's disease patients treated with a cholinesterase inhibitor in clinical practice
Gustavsson A; Parmler J; Ganguly R; Minthon L; Jonsson L
Conference publication: EUROPEAN HEART JOURNAL. 2007;28:260
Atrial fibrillation-costs and determinants of costs of illness in two European countries
Ericsson A; Jonsson L; Kindblom J; Almgren O; Edvardsson N
Conference publication: VALUE IN HEALTH. 2006;9(6):A346
Cost-effectiveness of rosuvastatin for cardiovascular prevention in high-risk populations in Sweden
Jonsson L; Ekman M; Karlsson G; Brun J
Corrigendum: ALZHEIMER DISEASE AND ASSOCIATED DISORDERS. 2006;20(2):125
Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. (vol 20, pg 49, 2006)
Jonsson L; Andreasen N; Kilander L; Soininen H; Waldemar G; Nygaard H; Winblad B; Eriksdotter JM; Hallikainen M; Wimo A
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2005;12:8
European Brain Council:: Epidemiology of brain diseases in Europe
Dodel R; Andlin-Sobocki P; Beghi E; Berg J; Jonsson L; Ekman M; Forsgren L; Jonsson B; Kobelt G; Lindgren P; Olesen J; Westphal M; Wittchen HU
Conference publication: NEUROBIOLOGY OF AGING. 2004;25:S481
Costs of formal dementia care in Europe
Zbrozek AS; Brandt AS; Jönsson L
Conference publication: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. 2004;43(5):464A
Cholesterol goal attainment is associated with lower incidence of cardiovascular events and cost of care
Jönsson L; Borgström F; Stålhammar J; Alemao E; Yin DDP
Conference publication: JOURNAL OF NEUROLOGY. 2004;251:44
Interferon beta-1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis:: results of a Markov disease model for Sweden and the UK
Kobelt G; Jönsson L; Fredrikson S
Thesis / dissertation: 2003
Economic evaluation of treatments for Alzheimer's disease
Jönsson, Linus
Conference publication: EUROPEAN HEART JOURNAL. 2003;24:246
Cost-effectiveness of ezetimibe co-administration in coronary artery disease patients not at goal with current statin therapy in Sweden
Cook JR; Jönsson L; Yin D; Alemao E; Huse D; Drummond M
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2003;48(9):S658
The burden of AS and the cost-effectiveness of treatment.
Kobelt G; Andlin-Sobocki P; Jönsson L; Brophy S; Calin A; Braun J
Conference publication: INTERNATIONAL PSYCHOGERIATRICS. 2003;15:156-157
Cost of care and quality of life in patients with Alzheimer's disease in relation to comorbidities:: Results from a Nordic study
Jönsson L; Eriksdotter-Jönhagen M; Kilander L; Soininen H; Waldemar G; Nygaard H
Review: PHARMACOECONOMICS (AUCKLAND). 2003;21(14):1025-1037
Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease
Jönsson L
Book chapter: DEMENTIA. 2002;p. 341-387
Costs of Dementia: A Review
Jönsson B; Jönsson L; Wimo A
Conference publication: OSTEOPOROSIS INTERNATIONAL. 2002;13:S45
Cost-effectiveness of alendronate for the treatment of male osteoprosis in Sweden
Borgström F; Sen SS; Johnell O; Jönsson B; Jönsson L; Zethreaus N
Conference publication: NEUROBIOLOGY OF AGING. 2002;23(1):S48
Costs of care and health-related quality of life in patients with Alzheimer's disease and their caregivers
Jönsson L; Jönhagen ME; Winblad B; Kilander L; Soininen H; Waldemar G; Nygaard H
Scholarly edition: 2001
Cost-utility analysis of Interferon Beta-1b in the treatment of different types of Multiple Sclerosis
Kobelt G; Jönsson L; Fredriksson S; Jönsson B
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2001;44(9):S158
Cost-effectiveness of infliximab (Remicade) in Sweden
Kobelt G; Jonsson L; Lindquist E; Eberhardt K
Conference publication: ARTHRITIS & RHEUMATOLOGY. 2001;44(9):S312
Economic consequences of the progression of rheumatoid arthritis in Sweden and the United Kingdom.
Kobelt G; Jonsson L; Lindgren P; Eberhardt K; Young A
Book chapter: DEMENTIA. 2000;p. 335-381
Costs of Dementia: A Review
Jönsson B; Jönsson L; Wimo A
Conference publication: OSTEOPOROSIS INTERNATIONAL. 2000;11:S9
Cost-effectiveness of Fosamax® (alendronate) for the treatment of osteoporosis and prevention of fractures
Johnell O; Jönsson B; Jönsson L; Black D
Conference publication: JOURNAL OF UROLOGY. 1998;159(5):302
Cost-effectiveness of tolterodine, a new treatment for symptoms of overactive bladder.
Kobelt G; Jonsson L; Lund AM
Show more

Grants

FINGER-Pro: Evidence-based health promotion interventions for healthy aging: adapting and implementing the FINGER multidomain model across different settings and sociocultural contexts
Swedish Research Council for Health Working Life and Welfare
1 October 2023 - 30 September 2029
PREDEM: precision diagnostics and treatment och cognitive disorders and prevention of dementia
VINNOVA
1 October 2021 - 30 September 2026
Alzheimer’s disease data-driven insights on individual outcomes of importance
Swedish Research Council for Health Working Life and Welfare
1 January 2019 - 31 December 2021

Employments

Professor, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 2023-

Degrees and Education

Docent, Karolinska Institutet, 2019
Doctor Of Philosophy, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 2003

About me

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI